Clinical Trials
19
Active:0
Completed:16
Trial Phases
3 Phases
Phase 2:3
Phase 4:14
Not Applicable:1
Drug Approvals
15
PHILIPPINES:14
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 4
14 (77.8%)Phase 2
3 (16.7%)Not Applicable
1 (5.6%)A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting Conditions
Phase 4
Not yet recruiting
- Conditions
- Post-operative PainBioequivalence Study in Healthy Subjects
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT06600282
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer
Phase 2
Terminated
- Conditions
- Hot FlashesBreast Cancer
- Interventions
- Drug: 0.8 mg RCN3028Drug: Placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06161792
- Locations
- 🇨🇳
Changhua Christain Hospital, Changhua, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Evaluate Bioequivalence of Burotam (1/1 g/Vial)
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05654090
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Evaluate Bioequivalence of Micafungin (50mg/Vial)
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05496725
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Evaluate the Efficacy and Safety of Lidocaine-Containing Hyaluronic Acid Filler in the Treatment of Nasolabial Folds.
Not Applicable
Completed
- Conditions
- Wrinkles Such as Nasolabial Folds
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05040594
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found